|
||
Phényléphrine Renaudin Pregnancy |
||
Phényléphrine Renaudin crosses the placenta at term.
Maternal use of Phényléphrine Renaudin during the first trimester of pregnancy is not strongly associated with an increased risk of fetal malformations; maternal dose and duration of therapy were not reported in available publications. Phényléphrine Renaudin is available over-the-counter for the symptomatic relief of nasal congestion. Decongestants are not the preferred agents for the treatment of rhinitis during pregnancy.
Oral Phényléphrine Renaudin should be avoided during the first trimester of pregnancy; short-term use (<3 days) of intranasal Phényléphrine Renaudin may be beneficial to some patients although its safety during pregnancy has not been studied. Phényléphrine Renaudin injection is used at delivery for the prevention and/or treatment of maternal hypotension associated with spinal anesthesia in women undergoing cesarean section. Phényléphrine Renaudin may be associated with a more favorable fetal acid base status than ephedrine; however, overall fetal outcomes appear to be similar. Nausea or vomiting may be less with Phényléphrine Renaudin than ephedrine but is also dependent upon blood pressure control. Phényléphrine Renaudin may be preferred in the absence of maternal bradycardia.
Small amounts of Phényléphrine Renaudin are secreted in breast milk. The manufacturer recommends that due to the potential for serious adverse reactions in nursing infants, a decision should be made to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
See references
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
|